Introduction
GVHD remains the single most important complication of allogeneic hematopoietic stem cell transplantation (HSCT).
1 GVHD is primarily mediated by donor T cells. 2 Daclizumab is a humanized monoclonal IgG1 that binds the a-chain of the IL-2 receptor (IL-2Ra CD25, TAC), [3] [4] [5] [6] blocks the action of IL-2 and inhibits the proliferation of antigen-activated T cells. 7, 8 Daclizumab was shown in Phase III trials to reduce significantly the rate of renal allograft rejection. 9 It has also been shown to have activity in the treatment of steroid-refractory acute GVHD. [10] [11] [12] [13] [14] Use of daclizumab, however, appears to be associated with an increased risk of infection, particularly in patients with GVHD. To investigate further the long-term results of daclizumab treatment, we reviewed our experience with daclizumab for the treatment of steroid-refractory acute GVHD after allogeneic HSCT.
Materials and methods

Patients
Between January 1993 and June 2000, 57 patients who underwent transplantation with allogeneic HSCT were treated with daclizumab (Zenapax, Roche Laboratories) for steroid-refractory acute GVHD at Memorial SloanKettering Cancer Center (Table 1 ). All patients treated with daclizumab are included in this report. Approval for this retrospective review was obtained from the Institutional Review Board.
All patients had been transplanted for hematologic malignancies or for non-malignant hematologic disorders. Fifty-six patients (98%) received a myeloablative conditioning regimen and one received a non-myeloablative regimen. Forty percent of patients received transplants from HLA-non-identical donors. The frequency of HLAmismatched donors was 62% in patients aged p18 years and 31% in those 418 years. For GVHD prophylaxis, 24 patients (42%) received cyclosporine with methotrexate or methylprednisolone, 32 patients (56%) received a T-cell-depleted (TCD) transplant and one patient received steroids alone. Twenty-four recipients of TCD transplants received antithymocyte globulin (ATG) to promote engraftment during the peri-transplant period, and recipients of T10B9.1A31 (T 10 B 9 )-depleted transplants received cyclosporine and methylprednisolone post-transplant. 15 Forty-eight patients (84%) received daclizumab for GVHD that developed following the primary transplant, two after a second transplant and seven (12%) after donor leukocyte infusion (DLI). The diagnosis of GVHD was made clinically and appropriate biopsies were performed for histologic confirmation, when feasible. Patients were diagnosed with steroid-refractory GVHD if they progressed (n ¼ 19) or did not respond by 7 days after initiation of steroids (n ¼ 25), or had a GVHD flare during or after tapering of the steroids (n ¼ 12). The episode of GVHD treated with daclizumab started at a median of 34 days after the most recent stem cell infusion or DLI (range, 10-277 days), and the median duration of treatment with methylprednisolone before daclizumab was 9 days (range, 1-38 days). One patient with late onset acute skin GVHD was started on daclizumab 1 day after initiation of steroids. The distributions of the stages and grades of acute GVHD at the start of daclizumab are shown in Table 2 . Twentynine (51%) patients had grades 3-4 GVHD. Patients aged p18 had significantly lower baseline GVHD scores (29% with grades 3-4) than those 418 (64% with grades 3-4, P ¼ 0.01). The initial treatment and response data of 17 patients were reported previously.
11
Treatment plan
Daclizumab was administered at 1 mg/kg intravenously (i.v.) on days 1, 8, 15, 22 and 29 (n ¼ 9), or on days 1, 4, 8, 15, 22 (n ¼ 48). In 15 patients, additional weekly doses were given. Other GVHD treatments were continued according to the patient's original prophylaxis, and methylprednisolone was administered i.v. at 2 mg/kg in divided doses for at least 7 days before attempting to taper steroids. In one patient, ATG was co-administered with daclizumab. Six patients who failed to respond to daclizumab received ATG as third line treatment, either during (n ¼ 4) or after (n ¼ 2) daclizumab administration. GVHD was scored at days 1, 15, 29 and 43 according to the consensus criteria. 16 
Response criteria
Response was scored on days 15, 29 and 43. Patients were evaluable for response in an organ if they had GVHD in that organ at the start of treatment with daclizumab or if GVHD developed after initiating daclizumab, but before the time point of evaluation. A complete response (CR) in an organ was defined as stage 0, and a partial response (PR) required reduction in at least one stage. For the overall response, a CR was defined as complete resolution of rash, normalization of bilirubin and absence of diarrhea due to GVHD without the use of antimotility agents. A PR was defined by a decrease in at least one stage in at least one Overall grade 5 (9) 23 (40) 14 (25) 15 (26) a Patients with grade I who were treated with daclizumab had persistent stage II skin GVHD that did not respond to systemic steroids. organ system without worsening in the other organ systems. Patients who received ATG or expired before day 43 were considered non-responders.
Infections
All severe, life-threatening or fatal infections during therapy and within 6 months following the last dose of daclizumab were documented through appropriate microbiological and imaging tests. Patients were considered to have CMV reactivation if they had a documented negative CMV antigenemia before daclizumab and developed a positive antigenemia or biopsy-proven CMV disease. Standard practice consisted of biweekly CMV antigenemia and once a week EBV-PCR (blood).
Statistical analysis
Analyses were performed as of 30 June 2006. Survival was assessed from the day of initiation with daclizumab therapy. Response to daclizumab was assessed at day 43. A landmark analysis was performed to assess survival differences among the responders and non-responders, conditional on survival at day 43. Survival curves were generated using the method of Kaplan-Meier and compared using the log-rank test. Responses to therapy were compared using Fisher's exact test.
Results
Response to therapy
The median number of daclizumab doses given was 5 (range 1-22), with 56% patients receiving five treatments. As reported in earlier studies, 10, 11, 14 no infusion-related side effects or serious clinical adverse events related to daclizumab were observed. Responses were seen as early as day 8 (not shown). On day 43 after initiation of therapy, 54% patients (n ¼ 31) had an improvement in their GVHD score (Figure 1 ). Higher response rates were seen in skin GVHD (64%) than in gastrointestinal (GI) (46%) or liver (20%) GVHD. Sixteen of 21 patients aged p18 years (76%) achieved either a CR (n ¼ 10) or PR (n ¼ 6). In comparison, 42% (15/36) adult patients achieved either a CR (n ¼ 9) or PR (n ¼ 6) (P ¼ 0.01).
Forty-five percent of recipients of HLA-matched allografts achieved either a CR or PR, while 79% of patients with HLA-mismatched donors achieved either a CR or PR (P ¼ 0.014). As noted above, although pediatric patients had lower baseline GVHD scores, they had a higher frequency of HLA-mismatch. Furthermore, the frequency of TCD transplants was similar in both pediatric and adult patients (57 vs 55%), suggesting that the lower baseline GVHD score and higher response to treatment with daclizumab in pediatric patients are not associated with differences in HLA-match or the use of T-cell depletion.
Infectious complications
Opportunistic infections developed in 54 patients (95%) within 6 months of initiating therapy with daclizumab (Tables 3 and 4 ). An additional patient died of a sepsis syndrome without a documented infection. Bacterial infections were documented in 50 patients (88%), fungal infections in 29 patients (51%) and viral infections in 30 patients (53%). All patients with fungal infections also had documented bacterial infections. CMV was the most common viral infection and was detected in 20 patients (35%), including 10/25 recipients of conventional grafts and 10/32 recipients of TCD grafts. Epstein-Barr virusassociated lymphoproliferative disorder (EBV-LPD) was documented in four patients (7%), all recipients of TCD grafts. The risk of infection was similar in pediatric and adult patients. In addition, there were no significant differences in the rates of infection (bacterial, fungal or viral) between recipients of TCD or conventional grafts.
Survival
Chronic GVHD developed in 14 patients (25%) after therapy with daclizumab. Fourteen patients (25%) remain alive following treatment with daclizumab with a median follow-up of 98 months, and eight are free of recurrent GVHD. Two patients died within a week of receiving the first dose of daclizumab, both with GVHD, pneumonia and multi-organ failure. The causes of death among all patients treated with daclizumab included GVHD and infection (34 patients, 79%), GVHD (two patients, 5%), chronic GVHD (one patient, 2%) and relapse of malignant disease (six patients, 14%) ( Table 5) . One additional patient who developed chronic GVHD died of complications of respiratory syncytial virus pneumonia almost 5 years after receiving daclizumab.
The median survival was 3.6 months. Mortality was higher in patients with grade 3-4 GVHD (only 0.15 survival at 4 years from treatment) than in patients with grade 1-2 GVHD (0.33 survival at 4 years, P ¼ 0.25). Survival in patients with grade 3-4 GVHD (median ¼ 2.0 months) was significantly shorter than in patients with grade 1-2 GVHD (median ¼ 5.1 months, P ¼ 0.001). Survival was not significantly different between patients with a CR or PR at day 43 (n ¼ 31; median survival 3.2 months; 95% CI; 2.3-7.7 months) and patients who were alive at day 43 but did not respond to daclizumab (n ¼ 13; median survival 1.5 months; 95% CI; 0.6 months -not evaluable, P ¼ 0.92). Pediatric patients achieved a median survival of 5.1 months, while median survival for adult patients was 2.7 months (P ¼ 0.02) (Figure 2) . Because of the small sample size, it was not possible to determine whether pediatric patients who responded at day 43 had a longer survival than those who did not. Only one pediatric patient died before day 43, and only 2/20 remaining patients did not have a response to daclizumab. Patients with HLAmatched related donors had a median survival of 3.7 months (95% CI; 1.8, 5.9 months), while those with nonidentical HLA-matched donors had a median survival of 3.1 months (95% CI; 2.3, 5.0 months, P ¼ 0.57).
Discussion
Earlier studies of daclizumab for steroid-refractory acute GVHD have reported response rates ranging from 40 to 100%. [10] [11] [12] [13] [14] In the phase II study, reported by Przepiorka et al., 11 29% of patients achieved a CR with 5 weekly doses of daclizumab and 47% when doses were given on days 1, 4, 8, 15 and 22. The overall response rate was 51% at day 43, with higher responses observed in skin than in gastrointestinal or liver GHVD. Consistent with these results, we observed a 54% response rate in the current study, with the highest response rates in skin GVHD. Patients aged p18 had lower baseline acute GVHD scores and higher response rates following treatment with daclizumab. Response to daclizumab was not associated with the type of graft, either TCD or conventional.
Two smaller studies have reported higher response rates with daclizumab. 12, 13 The higher overall response rate reported by Willenbacher et al. 12 was after a shorter follow-up of 28 days and consisted primarily of PR. In the more recent report by Srinivasan et al., 13 responses were seen in 12/12 patients who were treated with combinations of daclizumab and infliximab or ATG following a nonmyeloablative allogeneic HSCT. The higher responses noted in this study may be due to the combination of daclizumab with other agents. Consistent with other investigators, we found no significant clinical adverse events attributable to daclizumab administration.
A high incidence of infections has been reported in patients treated with second-line agents for steroid-refractory GVHD. In the current study, in addition to a high incidence of bacterial infections, CMV reactivation was documented in 35% of patients and fungal infections in 51% of patients (including two brain abscesses). A majority of patients had more than one type of infection. Furthermore, the rates and types of infection were not associated with the type of graft or with the patient's age. The risk of infection is consistent with that reported by others in second-line treatment for GVHD, whether with daclizumab or ATG. 12, [17] [18] [19] [20] It does not appear to be attributable to daclizumab specifically as recipients of renal allografts treated with daclizumab did not experience higher rates of infection. 9, 21 In the more recent study by Srinivasan et al., 13 the rates of infection were somewhat lower and in particular no invasive aspergillosis was diagnosed. CMV reactivation, however, was seen in 87% of patients at risk. The lower incidence of invasive aspergillosis may be due in part to systematic prophylaxis with intravenous lipid formulation amphotericin, but may also reflect the underlying diagnoses of the patients and a lower expected incidence of invasive aspergillosis. Nine of the patients were transplanted for solid tumors: two were in chronic phase CML and one had paroxysmal nocturnal hemoglobinuria. As expected, the high rate of infections in the present study was associated with poor survival. The majority of deaths were attributed to GVHD and infection. As noted in earlier studies in steroid-refractory GVHD, survival was significantly longer in patients with grades 1-2 acute GVHD compared to those with grades 3-4. The 5-year survival rate in this study was 25%. An additional concern in patients treated with anti-IL-2 receptor monoclonal antibodies for acute GVHD is the risk of relapse of the primary disease. Decreased or unchanged leukemia-free survival was reported in studies, in which a rat monoclonal antibody to the IL-2 receptor was given for GVHD prophylaxis. 22, 23 In a phase III study, in which patients with acute GVHD were randomized to steroids and daclizumab or steroids alone, a higher rate of relapse was observed in the combination arm (29 vs 17%). 24 Both the 100-day survival (77 vs 94%) and 1-year survival (29 vs 60%) were significantly decreased and no improvement in GVHD response was noted in the combination arm. This lack of improvement in first-line therapy was also observed when ATG was added to steroids for the initial treatment of acute GVHD. 25 In the latter study, however, no adverse effect on survival was seen. In contrast to the results of the recent randomized study, we observed relapse rates in daclizumab-treated patients comparable to previous reports of second-line daclizumab. 11, 12 Only 4/57 patients (7%) relapsed after daclizumab.
Daclizumab is active in the treatment of acute GVHD, with response rates equal or superior to those reported with ATG. 17, 18, 20 Like other second-line treatments, daclizumab is particularly effective in patients with skin GVHD and in pediatric patients. Patients who received daclizumab for second-line treatment of GVHD had significant morbidity and mortality due to infectious complications. However, it is always difficult to determine the relative contributions of the treatment and GVHD to a patient's overall risk for infection. Although the mortality rate is high in these patients, it appears to be lower than that reported in patients treated with ATG. 17, 18, 20 Given the lack of efficacy recently reported in a randomized study in which daclizumab was given as first-line therapy for acute GVHD, daclizumab should be reserved for patients with steroidrefractory acute GVHD. Careful patient selection and the use of aggressive prophylaxis against viral and fungal infections may reduce the burden of infection among this high-risk population.
